Status:
UNKNOWN
Improving the Diagnosis of Common Variable Immune Deficiency
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Jeffrey Modell Foundation
Conditions:
CVI - Common Variable Immunodeficiency
Eligibility:
All Genders
Brief Summary
This is an observational, case-control study with a single blood draw among two cohorts, patients with antibody deficiency (e.g., CVID) and healthy controls. Samples will be analyzed by mass cytometry...
Detailed Description
An increased susceptibility to bacterial and viral infections is the hallmark primary immunodeficiencies (PIDs). The most common PIDs requiring treatment with Ig replacement (SCIg or IVIg) is Common V...
Eligibility Criteria
Inclusion
- Diagnosis of antibody deficiency (CVID)
Exclusion
- \-
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03335605
Start Date
May 1 2019
End Date
June 1 2022
Last Update
March 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095